Study guide
6.4 Drug Information Practice, Diagnostic Test Accuracy & Pharmacoeconomics
PEBC Pharmacist Qualifying Examination Part I MCQ
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Canadian Pharmacy Regulatory Framework & Federal Legislation
1.1 Food and Drugs Act, Regulations, and Health Canada Oversight 1.2 Controlled Drugs and Substances Act (CDSA) & Controlled Substances Regulations (CSR) 1.3 NAPRA Drug Scheduling Framework & National Model Standards of Practice
2 Chapter 2: Ethics, Scope of Practice & Safety Culture
2.1 Professional Ethics, Fiduciary Duty & Health Information Privacy 2.2 Expanded Scope of Practice: Minor Ailments Prescribing, Renewals & Injections 2.3 Equity, Diversity, Inclusion, Cultural Safety & Continuous Quality Improvement
3 Chapter 3: Pharmaceutical Calculations & Posology
3.1 Concentrations, Dilutions, Alligations & Reconstitution 3.2 Dosing by Weight/BSA, Days Supply & Pediatric/Geriatric Dose Adjustments 3.3 IV Infusion Rates, Drop Factors, Osmolarity & Creatinine Clearance (Cockcroft-Gault)
4 Chapter 4: Compounding, Dispensing & Product Integrity
4.1 Non-Sterile Compounding & Beyond-Use Dating (NAPRA Standards) 4.2 Sterile Preparations & Hazardous Drug Handling (NAPRA / NIOSH Principles) 4.3 Prescription Verification, Auxiliary Labeling, Cold Chain & Medication Incident Prevention (ISMP Canada) 4.4 Dispensing Operations: Interchangeability, Adjudication, Compliance Packaging, Release & Inventory Control
5 Chapter 5: Clinical Pharmacology & Pharmacokinetics
5.1 Pharmacokinetic Principles: Clearance, Volume of Distribution, Half-life & Steady State 5.2 Cytochrome P450 Enzymes, Transporters & Significant Drug-Drug Interactions 5.3 Therapeutic Drug Monitoring (TDM), Narrow Therapeutic Index Drugs & Toxicities
6 Chapter 6: Evidence-Based Medicine & Literature Appraisal
6.1 Study Designs, Bias & Levels of Evidence in Clinical Research 6.2 Biostatistics: ARR, RRR, NNT, NNH, Confidence Intervals & P-values 6.3 Applying Canadian Practice Guidelines to Clinical Decision-Making 6.4 Drug Information Practice, Diagnostic Test Accuracy & Pharmacoeconomics
7 Chapter 7: Cardiovascular Pharmacotherapy: Hypertension, Dyslipidemia & CAD
7.1 Hypertension Management (Hypertension Canada Guidelines, Targets & Regimens) 7.2 Dyslipidemia & Atherosclerotic Cardiovascular Disease (CCS Guidelines & Statin Therapy) 7.3 Ischemic Heart Disease & Acute Coronary Syndromes (Antiplatelet & Antianginal Therapy)
8 Chapter 8: Cardiovascular Pharmacotherapy: Heart Failure, Arrhythmias & Anticoagulation
8.1 Heart Failure with Reduced & Preserved Ejection Fraction (GDMT & Monitoring) 8.2 Atrial Fibrillation, Arrhythmias & Rate vs. Rhythm Control 8.3 Venous Thromboembolism & Anticoagulation Therapy (DOACs, Warfarin & Thrombosis Canada)
9 Chapter 9: Endocrine & Metabolic Disorders
9.1 Type 2 Diabetes: Glycemic Targets, Non-Insulin Pharmacotherapy (Diabetes Canada) 9.2 Insulin Regimens, Type 1 Diabetes, Hypoglycemia & Diabetic Emergencies (DKA/HHS) 9.3 Thyroid Disorders & Osteoporosis (Diagnostic Parameters & Therapeutic Management)
10 Chapter 10: Respiratory & Gastrointestinal Disorders
10.1 Asthma Management & Exacerbations (CTS Guidelines, Relievers & Controllers) 10.2 Chronic Obstructive Pulmonary Disease (COPD) & Inhaler Delivery Systems 10.3 Gastroesophageal Reflux Disease (GERD), Peptic Ulcer Disease & GI Bleeding 10.4 Lower GI & Liver Disorders: Constipation, Diarrhea, IBS, IBD & Cirrhosis
11 Chapter 11: Infectious Diseases & Antimicrobial Stewardship
11.1 Respiratory Tract Infections: Otitis, Sinusitis, Pharyngitis, CAP & HAP 11.2 Urinary Tract, Skin/Soft Tissue & Sexually Transmitted Infections 11.3 Systemic Infections, Clostridioides difficile & Antimicrobial Stewardship Principles 11.4 HIV Prevention & Treatment, Viral Hepatitis, Tuberculosis & Fungal Infections
12 Chapter 12: Central Nervous System & Mental Health
12.1 Major Depressive Disorder & Anxiety Disorders (First-Line Agents & Safety) 12.2 Bipolar Disorder, Schizophrenia & Psychopharmacology Monitoring 12.3 Epilepsy, Seizure Types, Antiseizure Medications & Neuropathic Pain 12.4 Dementia, Parkinson Disease, Migraine, Insomnia & Restless Legs Syndrome
13 Chapter 13: Special Populations, Pain Management & Substance Use
13.1 Acute & Chronic Pain Management: Multimodal Analgesia & Opioid Stewardship 13.2 Substance Use Disorders: Opioid Agonist Therapy, Harm Reduction & Alcohol Withdrawal 13.3 Special Populations: Pharmacotherapy in Pregnancy, Lactation & Geriatrics (Deprescribing / Beers) 13.4 Palliative Care & Pediatric Pharmacotherapy
14 Chapter 14: Renal, Rheumatologic, Hematologic & Oncology Supportive Care
14.1 Chronic Kidney Disease, Acute Kidney Injury & Electrolyte Disorders 14.2 Osteoarthritis, Rheumatoid Arthritis & Gout 14.3 Anemias & Oncology Supportive Care
15 Chapter 15: Minor Ailments, Dermatology and Women's & Men's Health
15.1 Minor Ailments I: Allergic Rhinitis, Colds & Influenza, Eye and Ear Conditions 15.2 Minor Ailments II: Acne, Dermatitis, Psoriasis, Lice, Scabies & Sun Protection 15.3 Women's & Men's Health: Contraception, Emergency Contraception, Menopause, BPH, ED & Overactive Bladder
16 Chapter 16: Immunization & Health Promotion
16.1 Immunization Practice: NACI Recommendations, Administration, Cold Chain & Adverse Events 16.2 Health Promotion: Smoking Cessation, Weight Management, Screening & Social Determinants of Health
17 Chapter 17: Patient Care Process, Communication & Stewardship
17.1 The Patient Care Process: Assessment, Care Planning & Patient Interviewing 17.2 Patient Education, Device Counselling, Health Literacy & Overcoming Barriers 17.3 Interprofessional Collaboration, Pharmacy Workflow, Team Delegation & Drug Shortage Stewardship
6.4 Drug Information Practice, Diagnostic Test Accuracy & Pharmacoeconomics
Key Takeaways Explain This Topic AI
A systematic drug information response gathers background, identifies the real question, searches tertiary then secondary then primary sources, and follows up and documents.
Sensitivity is TP/(TP+FN) and specificity is TN/(TN+FP); a negative result on a highly sensitive test rules disease out, and a positive result on a highly specific test rules it in.
Predictive values depend on prevalence: the same test has a much lower positive predictive value in a low-prevalence population.
Cost-minimization assumes equal outcomes, cost-effectiveness uses natural units, cost-utility uses QALYs, and cost-benefit converts outcomes to money.
In Canada, CDA-AMC (formerly CADTH) or INESSS reviews cost-effectiveness, the pCPA negotiates prices, and each public plan makes its own listing decision.
Last updated: October 2026
Drug Information Practice, Diagnostic Test Accuracy & Pharmacoeconomics
The Knowledge and Expertise domain (11% of Part I) goes beyond study designs and treatment-effect statistics. Pharmacists must answer drug information requests systematically. They also interpret how well a diagnostic or screening test performs, and understand the economic analyses Canadian payers use to decide coverage. PEBC sample items include definitions such as the cost-benefit analysis and calculations such as odds ratios and number needed to treat.
1. A Systematic Approach to Drug Information Requests
A structured method avoids answering the wrong question. The classic modified systematic approach has seven steps:
Secure requester demographics: who is asking (patient, physician, nurse), how to reach them, and how urgent it is.
Obtain background information: the patient's age, weight, renal and hepatic function, diagnoses, current drugs and allergies, and why the question is being asked.
Determine and categorize the real question: for example, "Can she take this with warfarin?" may really be a question about managing an INR change.
Develop a search strategy: start with tertiary sources, then secondary , then primary literature.
Evaluate, analyze and synthesize the evidence for quality and relevance.
Formulate and communicate the response: a clear recommendation, its rationale and its limitations, in a form suited to the requester.
Follow up and document: confirm the outcome and keep a record of the question, sources and answer.
Source tier What it is Canadian examples
Tertiary Summaries of established knowledge; fast, but can be dated Compendium of Pharmaceuticals and Specialties (CPS), Compendium of Therapeutic Choices , RxFiles, Canadian product monographs in Health Canada's Drug Product Database (DPD)
Secondary Indexes and abstracting services used to find primary studies MEDLINE/PubMed, Embase, Cochrane Library
Primary Original research reports Randomized trials, cohort and case-control studies, case reports
Other Canadian resources include Canada Vigilance adverse reaction data (searchable through MedEffect), the Drug Shortages Canada database, and Canada's Drug Agency (CDA-AMC) , the former CADTH. CDA-AMC publishes reimbursement recommendations and health technology assessments.
2. Diagnostic and Screening Test Accuracy
A 2 × 2 table compares the test result with the true disease state:
- Disease present Disease absent
- Test positive True positive (TP) False positive (FP)
- Test negative False negative (FN) True negative (TN)
Sensitivity = TP ÷ (TP + FN): the proportion of people with the disease who test positive. A highly sensitive test rarely misses disease, so a negative result helps rule it out ("SnNout").
Specificity = TN ÷ (TN + FP): the proportion of people without the disease who test negative. A highly specific test rarely labels healthy people as diseased, so a positive result helps rule it in ("SpPin").
Positive predictive value (PPV) = TP ÷ (TP + FP): the chance that a person with a positive result really has the disease.
Negative predictive value (NPV) = TN ÷ (TN + FN).
Likelihood ratios: LR+ = sensitivity ÷ (1 − specificity), and LR− = (1 − sensitivity) ÷ specificity. An LR+ above 10 or an LR− below 0.1 shifts probability substantially.
Prevalence matters. Sensitivity and specificity are properties of the test, but PPV and NPV change with how common the disease is in the population tested.
Worked example: a test with 90% sensitivity and 80% specificity is used in 1,000 people with 10% prevalence.
100 have the disease: TP = 90, FN = 10.
900 do not: TN = 720, FP = 180.
PPV = 90 ÷ (90 + 180) = 33% . NPV = 720 ÷ 730 = 98.6% .
If the same test is used where prevalence is 50%, the PPV rises to about 82%. This is why screening low-risk populations generates many false positives.
3. Pharmacoeconomic Analyses
All four classic analyses measure costs in money. They differ in how they measure outcomes :
Analysis Outcome measure When it is used Result expressed as
Cost-minimization (CMA) Outcomes shown to be equivalent Choosing between bioequivalent generics or therapeutically equivalent drugs The cheaper option
Cost-effectiveness (CEA) Natural clinical units (mmHg lowered, events avoided, life-years gained) Comparing options with the same type of outcome Cost per unit of effect; incremental cost-effectiveness ratio (ICER)
Cost-utility (CUA) Quality-adjusted life-years (QALYs) Comparing across diseases; preferred by CDA-AMC Cost per QALY gained
Cost-benefit (CBA) Outcomes converted to money Programs with diverse outcomes (for example, a vaccination program) Net benefit or benefit-to-cost ratio
ICER = (Cost_new − Cost_old) ÷ (Effect_new − Effect_old). Example: a new drug costs $12,000 more per patient than standard care and gains 0.4 QALY, so the ICER is $12,000 ÷ 0.4 = $30,000 per QALY .
Perspective changes what is counted. A public payer perspective counts drug and health-system costs. A societal perspective also counts lost productivity and caregiver time.
Budget impact analysis estimates total spending for a payer if the drug is listed. It is not a value-for-money analysis.
Canadian process: after Health Canada approval, CDA-AMC (or INESSS in Quebec) reviews clinical and cost-effectiveness. The pan-Canadian Pharmaceutical Alliance (pCPA) then negotiates prices for public plans, and each plan decides on listing. Canada has no official cost-per-QALY threshold, although figures around $50,000 per QALY are often quoted as a reference point.
Note
A sensitivity analysis tests how robust an economic result is by varying uncertain inputs, such as drug price, efficacy or discount rate. It is unrelated to the sensitivity of a diagnostic test, despite the shared word.